Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Methylbenzoic Acid Methyl Ester SCHEMBL10539663 | 0.93 | TDP1 (1.00) | TDP1ALDH1A1LMNAMAPTCA1 | |
| 4-Methylbenzoic Acid Methyl Ester SCHEMBL137891 | 0.93 | TDP1 (1.00) | TDP1ALDH1A1LMNAMAPTCA1 | |
| SCHEMBL2337244 | 0.91 | CA1 (0.70) | TDP1ALDH1A1LMNAMAPTCA1 | |
| 4-Methylbenzoic Acid Methyl Ester SCHEMBL27908435 | 0.89 | TDP1 (0.91) | TDP1ALDH1A1LMNAMAPTCA1 | |
| 4-Methylbenzoic Acid Methyl Ester SCHEMBL7159509 | 0.89 | TDP1 (0.91) | TDP1ALDH1A1LMNAMAPTCA1 | |
| SCHEMBL13019491 | 0.87 | TDP1 (0.87) | TDP1ALDH1A1MAPTCA1CA2 | |
| SCHEMBL16604879 | 0.87 | TDP1 (0.87) | TDP1ALDH1A1MAPTCA1CA2 | |
| SCHEMBL2275652 | 0.87 | TDP1 (0.87) | TDP1ALDH1A1MAPTCA1CA2 | |
| 4-Methylbenzoic Acid Methyl Ester SCHEMBL28736599 | 0.87 | TDP1 (0.87) | TDP1ALDH1A1LMNAMAPTCA1 | |
| SCHEMBL10506033 | 0.85 | TDP1 (0.63) | TDP1ALDH1A1LMNAMAPTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| EP-0888389-B1 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | SURMODICS INC (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-0888389-A4 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | SURMODICS INC (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-0809490-A4 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871436-A4 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0835104-A4 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5942555-A | Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom | SURMODICS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0888389-A1 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | SurModics, Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0871436-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0835104-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0809490-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997034935-A1 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | BSI CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
| WO-1997002023-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| WO-1997002024-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0728482-A2 | Use of hcp specific compounds to enhance erythropoiesis | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0727211-A1 | Use of src SH2 specific compounds to treat a bone resorption disease | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996024343-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |
| EP-0085959-B1 | AROMATIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-04-19 | — | — | EP | disclosed |
| EP-0085959-A2 | Aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-08-17 | — | — | EP | disclosed |
| US-4040923-A | COATINGS, MOLDINGS | EASTMAN KODAK COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | TDP1 3037/4885ALDH1A1 244/4885LMNA 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.